Zimmer Biomet (NYSE:ZBH) Price Target Raised to $110.00

Zimmer Biomet (NYSE:ZBH) had its price objective increased by Stifel Nicolaus from $105.00 to $110.00 in a research report sent to investors on Thursday,Benzinga reports. Stifel Nicolaus currently has a buy rating on the medical equipment provider’s stock.

Several other analysts have also recently issued reports on ZBH. Robert W. Baird set a $92.00 target price on shares of Zimmer Biomet in a research note on Wednesday, April 29th. UBS Group restated a “buy” rating and set a $120.00 price target on shares of Zimmer Biomet in a research report on Thursday. Weiss Ratings raised shares of Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday. Sanford C. Bernstein increased their price objective on Zimmer Biomet from $91.00 to $93.00 and gave the stock a “market perform” rating in a research report on Thursday. Finally, Canaccord Genuity Group set a $83.00 price objective on Zimmer Biomet in a research note on Wednesday, April 29th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have issued a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $103.53.

Zimmer Biomet Trading Down 0.7%

Shares of ZBH opened at $96.54 on Thursday. The business’s 50-day moving average price is $90.17 and its 200-day moving average price is $90.13. Zimmer Biomet has a twelve month low of $79.12 and a twelve month high of $108.29. The stock has a market cap of $18.68 billion, a PE ratio of 23.49, a P/E/G ratio of 2.83 and a beta of 0.45. The company has a quick ratio of 0.95, a current ratio of 1.69 and a debt-to-equity ratio of 0.50.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.01 by $0.06. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The firm had revenue of $2.18 billion for the quarter, compared to the consensus estimate of $2.13 billion. During the same period in the prior year, the firm posted $2.07 earnings per share. The company’s revenue for the quarter was up 4.8% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, equities analysts forecast that Zimmer Biomet will post 8.53 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, July 31st. Shareholders of record on Thursday, June 25th were given a dividend of $0.24 per share. The ex-dividend date was Thursday, June 25th. This represents a $0.96 annualized dividend and a yield of 1.0%. Zimmer Biomet’s payout ratio is presently 23.36%.

Insider Buying and Selling

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the transaction, the insider owned 27,251 shares of the company’s stock, valued at $2,252,022.64. The trade was a 15.50% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.28% of the stock is currently owned by corporate insiders.

Institutional Trading of Zimmer Biomet

A number of hedge funds have recently made changes to their positions in ZBH. Main Management ETF Advisors LLC grew its position in Zimmer Biomet by 1.0% in the fourth quarter. Main Management ETF Advisors LLC now owns 10,962 shares of the medical equipment provider’s stock worth $986,000 after acquiring an additional 112 shares in the last quarter. Citizens National Bank Trust Department raised its position in Zimmer Biomet by 17.6% during the first quarter. Citizens National Bank Trust Department now owns 941 shares of the medical equipment provider’s stock valued at $85,000 after purchasing an additional 141 shares in the last quarter. LOM Asset Management Ltd lifted its stake in Zimmer Biomet by 21.5% during the fourth quarter. LOM Asset Management Ltd now owns 830 shares of the medical equipment provider’s stock worth $75,000 after purchasing an additional 147 shares during the last quarter. Oppenheimer & Co. Inc. lifted its stake in Zimmer Biomet by 0.8% during the fourth quarter. Oppenheimer & Co. Inc. now owns 20,363 shares of the medical equipment provider’s stock worth $1,831,000 after purchasing an additional 152 shares during the last quarter. Finally, TD Private Client Wealth LLC boosted its holdings in shares of Zimmer Biomet by 15.3% in the 4th quarter. TD Private Client Wealth LLC now owns 1,152 shares of the medical equipment provider’s stock worth $104,000 after purchasing an additional 153 shares in the last quarter. 88.89% of the stock is owned by institutional investors.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.